Company news

Share this article:
Merck and Addex Pharmaceuticals entered a deal to develop a drug candidate for schizophrenia, under which Merck will pay Addex up to $702 million in cash plus royalties. Geneva-based Addex will receive $22 million as an upfront payment and is eligible for up to $455 million in research, development, regulatory and sales milestones for the first product developed for two uses as well as up to $225 million in additional milestones for a second product developed for two uses.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.